Comparison of Early Fungicidal Activity and Mortality Between Daily Liposomal Amphotericin B and Daily Amphotericin B Deoxycholate for Cryptococcal Meningitis
Clinical Infectious Diseases · 05.02.2025 · 80 (1) · 153-159
DOI: 10.1093/cid/ciae326 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 29.06.2024. Verfasst von Sarah Kimuda und 17 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: Meningitis, Cryptococcal, Amphotericin B, Deoxycholic Acid, Antifungal Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCATS NIH HHS, UK Medical Research Council.
Abstract (Originalsprache)
Background
Limited data exist on the antifungal activity of daily liposomal amphotericin B with flucytosine induction regimens for cryptococcal meningitis, which are recommended in high-income countries. Liposomal amphotericin B monotherapy at 3 mg/kg previously failed to meet noninferiority criteria compared to amphotericin B deoxycholate in its registrational clinical trial. We aimed to compare the quantitative antifungal activity and mortality between daily amphotericin B deoxycholate and daily liposomal amphotericin B among persons with human immunodeficiency virus (HIV)–related cryptococcal meningitis receiving adjunctive flucytosine 100 mg/kg/day.
Methods
We analyzed data from 3 clinical studies involving participants with HIV-associated cryptococcal meningitis receiving either daily liposomal amphotericin B at 3 mg/kg/day with flucytosine (n = 94) or amphotericin B deoxycholate at 0.7–1.0 mg/kg/day with flucytosine (n = 404) as induction therapy. We compared participant baseline characteristics, cerebrospinal fluid (CSF) early fungicidal activity (EFA), and 10-week mortality.
Results
We included 498 participants in this analysis, of whom 201 had available EFA data (n = 46 liposomal amphotericin B; n = 155 amphotericin B deoxycholate). Overall, there is no statistical evidence that the antifungal activity of liposomal amphotericin B (mean EFA, 0.495 [95% confidence interval {CI}, .355–.634] log10 colony-forming units [CFU]/mL/day) differ from amphotericin B deoxycholate (mean EFA, 0.402 [95% CI, .360–.445] log10 CFU/mL) (P = .13). Mortality at 10 weeks trended lower for liposomal amphotericin B (28.2%) versus amphotericin B deoxycholate (34.6%) but was not statistically different when adjusting for baseline characteristics (adjusted hazard ratio, 0.74 [95% CI, .44–1.25]; P = .26).
Conclusions
Daily liposomal amphotericin B induction demonstrated a similar rate of CSF fungal clearance and 10-week mortality as amphotericin B deoxycholate when combined with flucytosine for the treatment of HIV-associated cryptococcal meningitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
- Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis.
- Department of Clinical Epidemiology and Biostatistics, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
- Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis.
ORCID-Profile: Sarah Kimuda
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
- UK Medical Research Council
- larger AMBITION-cm trial
- European and Developing Countries Clinical Trials Partnership
- NIH HHS
- Swedish International Development Cooperation Agency
- FIC NIH HHS
Zitieren
APA
Kimuda, S., Kwizera, R., Dai, B., Kigozi, E., Kasozi, D., Rutakingirwa, M. K., Tukundane, A., Shifah, N., Luggya, T., Luswata, A., Ndyetukira, J. F., Yueh, S. L., Mulwana, S., Wele, A., Bahr, N. C., Meya, D. B., Boulware, D. R., & Skipper, C. P. (2025). Comparison of Early Fungicidal Activity and Mortality Between Daily Liposomal Amphotericin B and Daily Amphotericin B Deoxycholate for Cryptococcal Meningitis. Clinical Infectious Diseases, 80(1), 153-159. https://doi.org/10.1093/cid/ciae326
Vancouver
Kimuda S, Kwizera R, Dai B, Kigozi E, Kasozi D, Rutakingirwa MK, et al. Comparison of Early Fungicidal Activity and Mortality Between Daily Liposomal Amphotericin B and Daily Amphotericin B Deoxycholate for Cryptococcal Meningitis. Clinical Infectious Diseases. 2025;80(1):153-159. doi:10.1093/cid/ciae326
BibTeX
@article{Kimuda2025,
author = {Kimuda, Sarah and Kwizera, Richard and Dai, Biyue and Kigozi, Enos and Kasozi, Derrick and Rutakingirwa, Morris K and Tukundane, Asmus and Shifah, Nabbaale and Luggya, Tony and Luswata, Andrew and Ndyetukira, Jane Frances and Yueh, Spencer L and Mulwana, Suzan and Wele, Abduljewad and Bahr, Nathan C and Meya, David B and Boulware, David R and Skipper, Caleb P},
title = {Comparison of Early Fungicidal Activity and Mortality Between Daily Liposomal Amphotericin B and Daily Amphotericin B Deoxycholate for Cryptococcal Meningitis},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {80},
number = {1},
pages = {153--159},
doi = {10.1093/cid/ciae326}
}
EUVIMED